Andelyn Biosciences

Activities: Manufacturing Research & Development

Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials.

Visit website

Profile

Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV Curator® Platform, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market.

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with...
  2. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf...
  3. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the...
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So...
  5. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little...

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

Related Content

Manufacturing

Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor

The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials
Manufacturing

Andelyn and Tern Therapeutics partner for late-stage process performance qualification of a treatment of CLN2 Batten disease

This collaboration reflects Andelyn’s broader mission to accelerate gene therapies from preclinical through commercial readiness
Research & Development

Andelyn and Amplo Biotechnology to manufacture gene therapies for diseases affecting the neuromuscular junction

The partnership reflects a shared commitment to advancing the development and improving access to life-changing therapies
Manufacturing

One family’s journey from diagnosis to gene replacement therapy

How the Krueger family, supported by clinicians, researchers, and manufacturers, accelerated a novel treatment for ultra-rare NEDAMSS in just 14 months
Cell & Gene Therapy

The challenges and trends in gene therapy

Three perspectives on the challenges and trends in gene therapy
Manufacturing

Andelyn Biosciences adds Stanton Lab CNS Capsids to AAV Curator Platform

Andelyn Biosciences expands AAV Curator® Platform offering to include Stanton Lab CNS Capsids through a license agreement from the Broad Institute of MIT and Harvard
Cell & Gene Therapy

Andelyn Biosciences produces viral vector for Nationwide Children’s Hospital using AAV Curator Platform

Andelyn Biosciences AAV Curator® Platform used to manufacture clinical grade viral vector for FDA-Authorised first-in-world Universal Donor CRISPR/AAV Transduced CAR-NK cells
Subscribe now